Fragmin (dalteparin sodium )
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Deep Vein Thrombosis
Conditions
Acute Deep Vein Thrombosis
Trial Timeline
Jun 1, 2007 → Jun 1, 2009
NCT ID
NCT00480636About Fragmin (dalteparin sodium )
Fragmin (dalteparin sodium ) is a pre-clinical stage product being developed by Pfizer for Acute Deep Vein Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00480636. Target conditions include Acute Deep Vein Thrombosis.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00480636 | Pre-clinical | Completed |
Competing Products
20 competing products in Acute Deep Vein Thrombosis